RESUMO
Background: Diabetes Mellitus Type 2 (DMT2), which is characterized by the raised blood sugar level due to insulin resistance in body cells, has now become global epidemic. This study was aimed to compare the efficacy of metformin and repaglinide monotherapy in patients with newly diagnosed DMT2. Methods: This randomized comparative prospective study was performed in a tertiary care hospital of Lahore. 108 Patients’ enrollment was made via simple random sampling technique and a developed inclusion and exclusion criteria. Patients were divided into metformin and repaglinide groups via lottery method. Self-designed proforma was applied for data collection. Data analysis was done in SPSS version 25.0. Results: There was no significant difference in the means of pretreatment (p=0.08) and posttreatment (p=0.10) fasting blood sugar levels between two groups, while significant differences between the means of pretreatment and posttreatment fasting blood sugar levels within metformin group (p=0.02) and repaglinide group (p=0.01) were noted. Likewise, there was no significant difference in the means of pretreatment (p=0.07) HbA1C levels of two groups; however, significant difference was observed in the means of posttreatment (p=0.04) HbA1C of two groups. Moreover, significant differences were also seen between the means of pretreatment and posttreatment HbA1C levels in both metformin group (p=0.03) and repaglinide group (p=0.01). Conclusions: This study suggests that although both metformin and repaglinide are effective in the new-onset T2DM managementz; however, reduction in fasting blood sugar level and HbA1c was more in repaglinide group.
RESUMO
OBJECTIVE：To provid e reference for hospital decision-maker to select and use repaglinide and naglinide reasonably. METHODS ：Through reviewing literautre ，guideline and instruction ，full score system was estalished for comunni- cation between pharmacists and physicians ；from the aspects of clinical necessity ，effectiveness，safety，economy，medical insu- rance attribute ，essential medicine attribute ，original research attribute ，drug packaging attribute ，drug market and enterprise attributes，the Mini health technology assessment （Mini HTA ）was carried out for repaglinide and nateglinide ，and scored on the basis of weight value. RESULTS ：Repaglinide and naglinide ’s final score were 77 and 74，respectively. For type 2 diabetes，both of them could reduce postprandial blood glucose ，and had less side effect and good safety. They were both included in the medical insurance list. Both of them were original varieties ，easy to store and had a long period of validity. Although they were expensive in the treatment of type 2 diabetes，their manufacturers had a good reputation and were widely used in the world ，which was a good choice for patients with type 2 diabetes. But they were different to certain extent ；repaglinide could be used in patients with poor renal function [eGFR ＜30 mL/min] without dose adjustment ；nateglinide should be adjusted according to eGFR for renal excretion. Repaglinide was essential medicine but nateglinide wasn ’t；repaglinide didn ’t need shading storage but nateglinide did. In addition ， a variety of liver drug enzyme inducers or inhibitors may interact with the two drugs ，and special groups should be used with. CONCLUSIONS ：Mini HTA provide reference for the selection and rational use of repaglinide and nateglinide ；patients with type 2 diabetes can select suitable drug according to their own conditions and needs. When combined with other drugs ，blood glucose should be closely monitored to prevent the occurrence of hypoglycemia.
RESUMO
Background: In India the number of people with diabetes is increasing day-by-day. Due to a sole “Asian Indian Phenotype,” Indians develop diabetes an era earlier and have an earlier onset of complications. Therefore, it is essential to evaluate more effective treatment strategies at an earlier stage of disease progression.Methods: The present study was prospective, open label, comparative, randomized, parallel group, single center study. Comparison of two post prandial active treatment groups over a period of 3 months. Sixty patients of either sex in the age group of 30-60years with newly diagnosed type II diabetes mellitus, with prandial blood glucose levels >180mg% and <250mg% at screening as per ADA. The effect of repaglinide and voglibose were observed on various parameters i.e. HbA1c, FBS, PBS, BMI.Results: In repaglinide group the mean change in HbA1c from baseline to 3 months was 8.05 to 7.04 (-1.01); on the other hand, in voglibose group from baseline to 3 months was 8.0 to 7.18 (-0.82). Whereas, FBS from 137.57 to 122.90 (-16.67) in repaglinide group; in voglibose group from 139.87 to 125.13 (-14.74). Repaglinide statistically highly significant than voglibose group in improving glycemic indices.Conclusions: Though repaglinide and voglibose were equally effective in improving glycemic indices yet repaglinide showed better results in improving HbA1c, FBG, PBS as compared with voglibose. Repaglinide had minimal side effects as compared to voglibose.
RESUMO
@#Present study evaluates efficacy and tolerability of fixed dose combination of Voglibose and Repaglinide in postprandial hyperglycemia (PPHG).A non-randomized, open labeled, non-comparative, multi-centric, study was conducted in 69 Type 2 diabetes mellitus (T2DM) patients, 53 (76.8%) men and 16 (23.2%) women. Each patient was administered a fixed dose combination of voglibose 0.3mg and repaglinide 1mg twice a day, just before each meal for 90 days. Fasting blood glucose (FBG) and postprandial blood glucose (PPBG) levels were measured at baseline (day zero), on day 30 and on day 90. Glycated Haemoglobin (HbA1c) was measured at baseline and on day 90. There was significant reduction in PPBG (31.2%), FBG (31.6%), and HbA1c (10.3%) on day 90 compared to baseline. Therefore fixed dose combination of voglibose 0.3mg and repaglinide 1mg has a considerable impact on PPBG control. This combination was found to be efficacious in controlling PPHG and no cases of hypoglycemia were reported.
RESUMO
OBJECTIVE:To investigate the effects of NOS1AP rs12742393 polymorphism on therapeutic efficacy of repaglinide in the treatment of type 2 diabetes mellitus(T2DM)in Chinese Han patients. METHODS:A total of 100 newly-diagnosed T2DM Han patients without any hypoglycemic therapy were selected from the Affiliated Hospital of Xuzhou Medical University during Aug. 2015-Mar. 2017. Based on routine therapy,they were additionally given Repaglinide tablets 1.0 mg,tid,for consecutive 8 weeks at least. PCR-RFLP was used to detect the genotypes at NOS1AP rs12742393 in patients. The levels of FPG,PPG,HbA1c, FINS,PINS,HOMA-IR,TC,TG,HDL-C and LDL-C were observed before and after treatment. RESULTS:There were 1 case of withdrawal and 1 case of follow-up loss,and 98 patients accomplished the study. There were 39 cases of NOS1AP rs12742393 AA genotype,42 cases of AC genotype and 17 cases of CC genotype,the frequency of them were 39.8％,42.9％,17.3％,which were in line with Hardy-Weinberg equilibrium (P>0.05). After 8 weeks,the levels of FPG,PPG,HbA1c,HOMA-IR,TC and TG were decreased significantly,compared with before treatment;the levels of FINS and PINS were increased significantly, compared with before treatment,with statistical significance (P<0.05). Before treatment,there was no statistical significance in each index among different genotypes (P>0.05). After treatment,the levels of FPG,PPG and HbA1c in all genotypes,the level of HOMA-IR in AA genotypes,the level of TC in CC genotype,the level of TG in AA and CC genotype were decreased significantly;the level of PINS in all genotype,the level of FINS in AC and CC genotype and the level of HOMA-IR in CC genotype were increased significantly;the levels of FPG and PPG in CC genotype were significantly higher than AA and AC genotype,and the decrease of two indexes than before treatment were significantly less than AA and AC genotype;the level of FPG in AC genotype was significantly higher than AA genotype;the level and increase than before treatment of FINS,and the level of HOMA-IR in AC and CC genotype was significantly higher than AA genotype;there was statistical significance in the change than before treatment of HOMA-IR among all genotypes (P<0.05). There was no statistical significance in other indexes among all groups before and after treatment(P>0.05). CONCLUSIONS:NOS1AP rs12742393 polymorphism may influence therapeutic efficacy of repaglinide in the treatment of T2DM in Chinese Han patients,and risk gene C may weaken therapeutic efficacy of repaglinide by influencing the levels of FPG,PPG,FINS and HOMA-IR.
RESUMO
OBJECTIVE:To evaluate the effectiveness and safety of repaglinide combined with metformin versus glimepiride combined with metformin in the treatment of type 2 diabetes mellitus (T2DM),and to provide evidence-based reference for the clinic. METHODS:Retrieved from CJFD, VIP, Wanfang database, PubMed, Embase, Medline and Cochrane Library, randomized controlled trials (RCTs) about therapeutic efficacy (HbA1c, FPG, 2 hPG) and safety (the incidence of ADR,hypoglycemia and gastrointestinal reaction)of repaglinide combined with metformin(trial group)versus glimepiride combined with metformin(control group)in the treatment of T2DM were collected. Meta-analysis was performed by using Rev Man 5.2 statistical software after data extraction and quality evaluation with Cochrane systematic evaluation manual. RESULTS:A total of 12 RCTs were included,involving 957 patients. Results of Meta-analysis showed that the decrease of 2 hPG in trial group was significantly better than control group,with statistical significance [MD=-0.70,95％CI(-1.02,-0.38),P<0.001]. There was no statistical significance in the decrease of HbA1c [MD=0.00,95％CI(-0.24,0.25),P=0.98] or FPG [MD=0.10,95％CI(-0.17,0.36),P=0.47],the incidence of ADR [OR=0.54,95％CI(0.28,1.06),P=0.07],hypoglycemia [OR=0.52,95％CI(0.13,2.06),P=0.35] or gastrointestinal reactions [OR=0.60,95％CI(0.15,2.41),P=0.47] between 2 groups. CONCLUSIONS:Repaglinide combined with metformin is better than glimepiride combined with metformin in reducing 2 hPG,but both of them have similar safety.
RESUMO
Objective To analyze the clinical effect of insulin detemir combined with repaglinide in the treatment of type 2 diabetes mellitus (T2DM).Methods From January 2016 to July 2017,100 patients with T2DM in the First People＇s Hospital of Jiande were randomly divided into the observation group and control group according to the digital table,with 50 cases in each group.The control group was treated by low neutral protamine zinc human insulin( N) and repaglinide,the observation group was treated by insulin detemir combined with repaglinide .The clinical treatment effect was compared between the two groups.Results The total effective rate of the observation group was 96%,which was significantly higher than 78% of the control group,the difference was statistically signifi-cant (χ2＝22.014,P＜0.05).Before treatment,the biochemical indicators between the two groups had no statistically significant differences (t ＝0.125,1.225,0.125,1.225,0.142,all P ＞0.05).After treatment,the biochemical indicators of the observation group were better than those of the control group (t ＝5.064,5.035,5.064,5.035,5.165,all P ＜0.05 ).Conclusion Though insulin detemir combined with repaglinide and traditional insulin combined with repaglinide can lower blood glucose in patients with T 2DM,but the former combination effect is better.
RESUMO
Objective To systematically evaluate the clinical effect and safety of repaglinide and metformin for treating diabetes mellitus (MD) of secondary failure of sulfonylurea (SFS).Methods The randomized controlled trials (RCT) at home and abroad on the comparison of effect and safety of repaglinide and metformin in treating MD with SFS were retrieved.The modified Jadad scale was employed to evaluate the literature quality.The RevMan5.3.1 software was used for conducting the meta analysis.Results A total of 10 RCT were included.The meta-analysis results showed that compared with metformin for treating MA with SFS,repaglinide decreased the fasting blood glucose effectively (MD=-2.30,95 ％ CI:-2.53--2.06,P＜0.01),increased the fasting C-peptide (MD=0.06,95％CI:0.02-0.11,P=0.01),reduced the postprandial 2 h blood glucose (MD=-2.17,95 ％CI:-2.44-1.89,P＜0.01) and decreased glycosylated hemoglobin (MD=-2.60,95％CI:-3.21--2.00,P＜0.01) as well as the adverse reactions (RR=0.05,95％CI:0.02-0.09,P＜0.01).However,there was no statistical difference in fasting insulin between the repaglinide and metformin groups (MD=0.18,95％CI:-0.18-0.54,P=0.32).Conclusion Currently evidences suggest that repaglinide is superior to metformin for treating MD with SFS.
RESUMO
Objective To analyze the clinical efficacy and value of insulin glargine combined with repaglin-ide in the treatment of type 2 diabetes patients with chronic renal insufficiency.Methods 1 16 type 2 diabetes patients with chronic renal failure were divided into two groups according to the time of treatment.58 cases in the control group received premixed insulin treatment,while 58 cases in the observation group were given repaglinide plus insulin glargine,its clinical value was compared between the two groups.Results The FPG,2h PG,HbAlc of the observation group were (5.90 ±0.62)mmol/L,(7.03 ±0.65)mmol/L,(6.20 ±0.64)%,which were significantly reduced compared with before treatment(t=8.01,7.73,8.82,all P<0.05),and compared with the control group, the differences were statistically significant (t=7.23,6.83,7.73,all P<0.05 ).The SCr,BUN,24h UAE of the observation group were (90.90 ±8.43)μmol/L,(6.70 ±0.74)mmol/L,(1.20 ±0.34)g,which were significantly reduced than before treatment (t=7.69,7.89,8.02,all P<0.05),and compared with the control group,the differ-ences were statistically significant(t=6.83,7.03,6.57,all P<0.05).The incidence rate of adverse reaction of the observation group was 12.07%,which was significantly lower than 34.48% of the control group(χ2 =8.29,P<0.05 ),the main adverse reactions were hypoglycemia,patients with self-eating or oral syrup remission.Conclusion Insulin glargine combined with repaglinide in the treatment of type 2 diabetes patients with chronic renal function can control blood sugar levels,improve renal function and reduce adverse reactions,it is effective,safe,reliable and worthy of promotion.
RESUMO
Objective:To study the solubility of repaglinide in meglumine aqueous solution. Methods: In order to increase the solubility of repaglinide, meglumine was used to react with repaglinide and obtain a molecular complex. The structure and composition of meglumine-repaglinide complex was analyzed by DSC, HPLC and HPLC-MS. Results:Meglumine and repaglinide formed a molecu-lar complex, and their best molar ratio was 1 ∶1. With the concentration increase of meglumine, the solubility of repaglinide also in-creased. The stability of molecular complexes decreased with the temperature increase. Conclusion:Meglumine plays a good role in the solubilization of repaglinide.
RESUMO
Objective To explore the ziggy joint amomum six columns nai jun pill in patients with diabetic nephropathy urinary inhibition c and serum c-reactive protein levels.MethodsSelect 80 patients with diagnosis of diabetic nephropathy, randomly divided into 2 groups, 40 cases in each group.Craig column nai treatment, control group given on the basis of the observation group in the control group given six jun pill treatment, treatment of 12 weeks, before and after treatment were detected blood glucose (FBG), glycosylated hemoglobin (HbA1C), urinary inhibition c (CysC) and serum c-reactive protein (CRP) and 24 h urinary microalbumin urine trace albumin (24 hUAE) changes.ResultsCompared with before treatment, 24 hUAECysC, CRP and 2 group were lower (P< 0.05);Compared with control group, 24 huae CysC, CRP and the observation group were lower (P< 0.05), the clinical curative effect is higher (P< 0.05), and high safety.ConclusionZiggy joint amomum six columns nai jun pill treatment of the diabetic nephropathy is a effective way, and can significantly reduce serum CysC, CRP levels.
RESUMO
Objective Tocompare the clinical efficacy of Glipizide and Repaglinide in the treatment of newly diagnosed type 2 diabetes (T2DM).Methods The clinical data of 104 patients with newly diagnosed T2DM were retrospectively analyzed,among them,54 cases were treated with Glipizide (group G),and 50 eases were treated with Repaglinide (group R).The levels of FPG,2hPG,HbA1c,TC,TG and HDL-C before and after treatment and HbA1c compliance rates,BMI variation and incidences of hypoglycemia between two groups were compared.Results The levels ofFPG,2hPG and HbA1c after treatment in the two groups were significantly lower than those before treatment (P ＜ 0.05),and there were no significant difference between the groups.There were no significant changes in TG,TC and HDL-C levels before and after treatment in the two groups.There were no significant changes in HbA1c compliance rates between the two groups,and the BMI variation and incidences of hypoglycemia in the group G were significantly lower than those in the group R (P ＜ 0.05).Conclusion BothGlipizide and Repaglinide in the treatment of T2DM can reduce blood glucose effectively,and no significant effect on blood lipids,But Glipizide has more advantages in controlling BMI and reducing hypoglycemia.
RESUMO
Objective This study examined the effects of repaglinide on the proliferation, differentiation, and apoptosis of mouse pre-osteoblasts MC3T3-E1 subclone 14 cell under high glucose condition.Methods MC3T3-E1 cells cultured in vitro for 48h were divided into the following groups: control group and repaglinide with different concentrations (0.01, 0.1, 1, and 10 μmol/L).Cell proliferation was measured by CCK-8 assay.mRNA levels of type I collagen(COL-Ⅰ), osteopontin(OPN) and alkaline phosphatase(ALP) were assayed using quantitative real-time PCR.Expression of apoptosis related proteins (Bcl-2, Bax) was measured by western blot analysis.Results (1)Compared with control group, the proliferation rate of repaglinide with different concentrations increased, while the proliferation rate of the 1 μmol/L repaglinide group significantly higher than that of the control group(P0.05).Compared with control group, the OPN and ALP mRNA expression increased significantly in the 1 μmol/L repaglinide group(P<0.05), while the OPN expression was significantly declined in the 10 μmol/L repaglinide group(P<0.05).(3)The protein expression of Bcl-2 was positively related with repaglinide concentration(P<0.05), while the protein expression of Bax went down in the 1 and 10 μmol/L repaglinide groups(P<0.05).Conclusion When exposed to high glucose concentration, repaglinide in a certain concentration range may promote the proliferation and differentiation of MC3T3-E1 subclone 14, while restrain its apoptosis.
RESUMO
OBJECTIVE:To comparison the clinical efficacy and safety of sitagliptin and Repaglinide in the treatment of new-ly diagnosed patients with type 2 diabetes mellitus. METHODS:214 newly diagnosed patients with type 2 diabetes mellitus were randomly divided into study group and control group with 107 cases in each group according to random number table method. Both group received routine diabetes diet,health education and suitable exercise. Control group was treated with Repaglinide tablet 1.0 mg,tid;while study group was treat with Sitagliptin tablet 100 mg,qd. Lab indexes,FBG,PBG,HbA1c and BMI were observed in 2 groups before and after treatment. ADR were compared between 2 groups. RESULTS:There was no statistical significance in lab indexes between 2 groups before and after treatment (P>0.05). After treatment,FBG,PBG,HbA1c were significantly de-creased significantly in 2 groups,with statistical significance (P0.05). BMI of 2 groups were increased significantly,and the study group was higher than the contrd group,with statistical sighificance (P0.05). CONCLUSIONS:Sitagliptin is similar with repaglinide in therapeutic efficacy;both can effectively reduce blood glucose of elderly patients with newly diagnosed type 2 diabetes mellitus,and the incidence of hypo-glycemia was low,the saterty was good,but sitagliptin has a better control of BMI in patients.
RESUMO
Objective:To explore therapeutic effect of repaglinide on patients with type 2 diabetes mellitus (T2DM) complicated atherosclerosis (AS).Methods:A total of 120 T2DM + AS patients treated in our hospital from Mar 2012 to May 2014 were selected.They were randomly and equally divided into repaglinide group (received repaglin- ide treatment)and glipizide group (received glipizide treatment).Fasting blood glucose (FBG)and 2h postprandial blood glucose (2hPG)levels before and after treatment,serum levels of high sensitive C reactive protein (hsCRP) and oxidized low density lipoprotein (oxLDL)after treatment,and patients'satisfaction on treatment were com- pared and analyzed between two groups.Results:Compared with before treatment,there were significant reductions in levels of FBG and 2hPG in both groups after treatment (P<0.01 all);compared with glipizide group,there were significant reductions in levels of FBG [(6.94±0.41)mmol/L vs.(6.05±0.54)mmol/L],2hPG [(8.03±0.74) mmol/L vs.(7.66±0.78)mmol/L],serum hsCRP [(5.75±0.26)mg/L vs.(4.71±0.32)mg/L]and serum ox- LDL [(98.30±25.05)μg/dl vs.(52.21±17.50)μg/dl]after treatment in repaglinide group,P<0.01 all.Satis- faction rate in repaglinide group was significantly higher than that of glipizide group (93.33% vs.60.00%),P<0.01. Conclusion:Repaglinide possesses significant therapeutic effect on patients with type 2 diabetes mellitus com- plicated atherosclerosis.It can significantly reduce blood glucose,blood lipid and serum hsCRP levels.
RESUMO
Objective To explore the effects of glargine combined metformin and repaglinide combined metformin treatment on metabolism of free radicals in elderly patients with type 2 diabetes(T2DM ) .Methods Selected 90 cases of elderly T2DM pa‐tients were divided into 2 groups:group A (glargine combined metformin treatment group) ,group B (repaglinide combined met‐formin treatment group) .Each group had 45 patients ,they were all treated for four weeks in antidiabetic therapy ,select 40 healthy people in physical examination center of hospital as controls .They were measured in patients with fasting plasma glucose (FPG) ,2h postprandial blood glucose(2hPG) ,malondialdehyde (MDA) ,glutathione peroxidase (GSH‐PX) ,8‐iso‐prostane (8‐iso‐PGF2a) , Hcy and so on ,before and after treatment .Results (1)Before treatment ,the FPG ,2hPG ,HbA1c ,MDA ,8‐iso‐PGF2a ,Hcy of group A and B were higher than the control group ,while the level of GSH‐PX was lower than the control group ,the difference was statis‐tically significant(P0 .05) ,While 8‐iso‐PGF2a , MDA ,Hcy of group A had a bigger decline rate than group B ,the GSH‐PX in group A increased more compared with group B ,the difference was statistically significant (P<0 .05) .Conclusion (1)There is a high oxidative stress state in elderly patients with T2DM ;(2)Both treatments could improve diabetics oxidative stress levels ,but glarginecombined metformin to reduce diabetics oxi‐dative stress is superior to repaglinide combined metformin .
RESUMO
Type 2 diabetes (T2DM) is a progressive insulin secretory defect accompanied by resistance to insulin, and thereby making glycemic control a major concern in the treatment of these patients. Oral drug administration, though a popular option for its non-invasiveness, suffer from poor bioavailability. It could be related to the efflux transport of intestinal P-glycoprotein (Pgp). In the present study, we explored the binding interactions of antidiabetic drugs i.e., sulfonylurea drugs (glimepiride, glipizide, glyburide) and rapid acting insulin secretagogues viz., nateglinide, repaglinide and rosiglitazone; and Pgp inhibitors i.e., Generation I (verapamil and tamoxifen), III (tetradrine and tariquidar), and natural inhibitors (fumagillin and piperine) in mouse Pgp model. Our results revealed that fumagillin piperine and verapamil possess maximum interaction energies with Pgp compared to antidiabetic drugs. These observations elucidate the role of fumagillin and piperine as potential natural compounds which could intervene in the efflux action of Pgp in extruding the antidiabetic drugs and may have implications for increasing efficacy of oral antidiabetic therapy.
RESUMO
OBJECTIVE:To systematically review the efficacy and safety of glipiaide versus repaglinide in treatment of type 2 diabetes and provide evidence-based reference for the clinical treatment. METHODS:PubMed,EMBase,Medline,Cochrane Li-brary,CJFD,VIP and WanFang database were retrieved to collect the randomized controlled trials(RCT)of the efficacy and safety of glipizide(test group)versus repaglinide(control group)in the treatment of type 2 diabetes. After the quality evaluation and in-formation collection of clinical studies with inclusion criteria,Rev Man 5.2 software was conducted for Meta-analysis. RESULTS:There were totally 10 RCTs,involving 1 022 patients. Meta-analysis results showed that the HbA1c levels [MD=0.43,95%CI (0.20,0.65),P<0.001],2 h postprandial plasma glucose levels [MD=0.49,95% CI(0.04,0.94),P=0.03] and hypoglycemia inci-dence [OR=2.99,95%CI(1.83,4.88),P<0.001] in test group were significantly higher than control group. There was no signifi-cant difference in the fasting plasma glucose level in 2 groups[MD=-0.14,95%CI(-0.44,0.16),P=0.35]. CONCLUSIONS:Re-paglinide has better efficacy and safety than glipizide in the treatment of type 2 diabetes. Limited by the methodological quality and sample amount of included studies,it remains to be verified by RCT with large sample,strict design and long-term follow-up.
RESUMO
Objective To analyse the effect of repaglinide combined with Zhenqi Jiangtang Capsules on βcell function in elderly patients with type 2 diabetes mellitus.Methods 60 elderly patients were collected from harbour branch of Hainan provincial People's hospital, who were diagnosed with type 2 diabetes mellitus .All patients were randomly divided into experimental group and control group, 30 cases in each group, 2 groups of patients were given control diet, moderate exercise, and other conventional adjuvant therapy.Control group was treated with repaglinide orally on the basis of routine adjuvant treatment, 1 mg/times, three times per day,experimental group were given Zhenqi Jiangtang Capsules based on the treatment in control group,4 grains/times,three times per day.Both groups were treated for 4 weeks, after the end of treatment, blood glucose levels,serum insulin levels,βcell function and serum lipids in all patients were detected.ResuIts After treatment, compared with control group, the levels of blood glucose, HbA1c and AUCg in experimental group were significantly lower ( P<0.05 );the insulin levels 30 min,60 min, 120 min after meal were significantly higher (P<0.05);the HOMA-IR of patients was significantly lower(P<0.05);IRG, AUCi and AUCi/AUCg were significantly higher (P<0.05);the serum TC, TG, LDL levels were significantly lower, serum HDL levels were significantly higher(P<0.05).ConcIusion Repaglinide combined with Zhenqi Jiangtang Capsules can significantly reduce the blood glucose and lipid levels in elderly patients with type 2 diabetes, improve the function of pancreatic beta cells, promote postprandial insulin secretion and improve insulin resistance.
RESUMO
Repaglinide is one of the most commonly used oral antidiabetic drugs. It can lower postprandial plasma glucose by means of initiating early-phase insulin release through closing the ATP-dependent potassium channels. Phamacogenomics is a branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism. The progress of phamacogenomic study on repaglinide is summarized in this article.